Clinical Trials Browser

Phase 1/2 × Lymphoma, T-Cell, Peripheral × tazemetostat × Clear all

NCT07209163 2025-10-06

Combination Therapy With Tazemetostat in Relapsed and Refractory Peripheral T-cell Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell, Peripheral